

ORIGINAL ARTICLE

Relationship of Neutrophil to Lymphocytis Ratio with Success of Thrombolysis in Patients of STEMIASMA KAMAL¹, SHAZIA SIDDIQUE², KHADIJA MUNEER³, ASIFA KAMAL⁴, MAHRUKH MANSOOR KHOSA⁵, ANEEQA ILYAS⁶¹Assistant Professor of Medicine, Services Institute of Medical Sciences/Services Hospital, Lahore²MBBS, FCPS (Medicine), Jinnah Hospital LHR³MBBS, FCPS (Medicine), SHL⁴Associate Professor Statistics LCWU⁵MBBS, FCPS, (Cardiology), MO PIC LHR⁶MBBS, FCPS (Medicine), SHLCorrespondence to: Asma Kamal, Email: drasmakamal@gmail.com, Cell: 0336-4154436**ABSTRACT****Objectives:** To determine the frequency of success of thrombolysis using SK in patients of STEMI, To investigate the association of success of thrombolysis with NLR in patients of STEMI.**Methodology:** A descriptive cross sectional study was carried out at Coronary Care Unit (CCU) of Services Hospital, Lahore. The sample size of 130 patients were enrolled by non-probability consecutive sampling. In this study all male and female patients from 25 to 100 years of age with STEMI who were given SK were included from CCU of Services Hospital, Lahore using non probability consecutive sampling. NLR was calculated. Success of thrombolytic therapy was determined by relief of chest pain & resolution of $\geq 50\%$ ST-elevations (STE) in ECG taken 90 minutes after completion of SK.**Results:** In this study, there were total 130 cases and out of these 72 (55.38%) were males and 58 (44.62%) were females. High NLR was seen in 43 (33.08%) of the cases. Successful thrombolysis was observed in 99 (76.15%) of the cases. Successful thrombolysis was observed in 29 (67.44%) cases with high NLR and 70 (80.46%) cases with low. There was no significant association of NLR, BMI, smoking, DM and HTN with successful thrombolysis.**Practical Implication of this Study:** is that in our resource limited country NLR is one of cheapest test to access severity and prognosis so patients with high NLR can be referred early for intervention even if responded successfully to thrombolysis as complications of STEMI are frequent in high NLR patients as compared to lower NLR.**Conclusion:** Successful thrombolysis was seen in almost 3/4 cases in acute STEMI. Although a cheaper and readily available prognostic tool, no statistically significant association was found in terms of the admission NLR and the success of thrombolysis. Moreover, there was no significant association in terms of any of the confounders of the study.**Keywords:** Thrombolysis, Streptokinase (SK), Neutrophil to Lymphocytis Ratio (NLR), ST Segment Elevation MI (STEMI)**INTRODUCTION**Myocardial infarction (MI) results from rupture of atheromatous plaque and thrombosis in an epicardial vessels leading to imbalance in demand and supply of oxygen to Myocardium.¹

Pathophysiologically myocardial infarction is irreversible myocardial cell death resulting from ischaemia that is biochemically supported via cardiac enzymes, ECG changes, to detect myocardial injury and necrosis.

The atheromatous plaque starts with thickening of arterial intima without or minimal inflammation of cells and this can be observed shortly after birth. Afterward lipid rich necrotic core surrounded through fibrous tissue is formed. Finally vulnerable plaque consists of necrotic core with thin fibrous cap deficient in smooth muscles and infiltrated with inflammatory cells is found.^{2,3}The mortality rate in myocardial infarction is 30% and half of deaths occur before arrival in the hospital. Other 5% to 10% die within 1st year after MI and half are re-hospitalized within 1st year of MI.

The Prognosis of MI depends on extent of infarct, residual left ventricle function whether patient underwent revascularization.

The incidence of Coronary Artery Disease (CAD) related mortality is projected to rise dramatically in developing countries including India, Middle East, Latin America and Sub-Saharan Africa with approximately 80 percent increase from 1990's to 2020's.^{4,5}A significant reperfusion approach is fibrinolysis, particularly, where primary PCI can't be offered within timelines. Benefit of fibrinolytic therapy in patients with STEMI is well established. Largest benefit seen when administered within 12 hours after the symptomatic onset and in patients with highest cardiovascular risk.^{6,7}

Atherosclerosis is a multifactorial disease. And there is role of inflammation in formation and development of atherosclerotic plaque. Two inflammatory markers, neutrophil-to-lymphocyte ratio (NLR) and red cell distribution width (RDW) are used to find out risk of mortality plus adverse cardiovascular outcomes in patients having acute myocardial infarction.

In cardiovascular disease, White blood cell count and its subtypes are considered to be classic markers of inflammation. NLR was considered to be a inflammatory marker in cardiac and non-cardiac diseases too. So, it is used as predictor of long term mortality in patients undergoing PCI in STEMI.⁸

As neutrophil and lymphocyte values are readily available in routine blood count analysis, So NLR may be used as cost effective predictor of cardiovascular complications and inflammation.

MATERIALS AND METHODSA descriptive cross sectional study was carried out at Coronary Care Unit (CCU) of Services Hospital, Lahore. The sample size of 130 patients was calculated with 8% margin of error and 95% confidence level. All the patients were enrolled by non-probability consecutive sampling. In this study all male and female patients from 25 to 100 years of age with STEMI who were given SK were included from CCU of Services Hospital, Lahore using non probability consecutive sampling. NLR was calculated. Success of thrombolytic therapy was determined by relief of chest pain & resolution of $\geq 50\%$ ST-elevations (STE) in ECG taken 90 minutes after completion of SK. All the data was collected on the predesigned performa. Data was entered and analyzed by using SPSS 25.0. all the quantitative variables were presented by mean+SD and qualitative with frequencies and percentages. Association between success of thrombosis and risk factors were analyzed by using Chi-square test. P-value <0.05 was considered as significant.**Statistical Technique:** Descriptive Statistics, Chi Square Test**RESULTS**

The study shows that there were total 130 cases and out of these 72 (55.38%) were males and 58 (44.62%) were females. Success of thrombolysis was observed in 99 (76.15%) of the cases (Figure 1). High NLR was seen in 43 (33.08%) and low NLR in 87 (66.92%) of the cases (Figure 2).




Figure 1: Successful Thrombolysis in Study Subjects




Figure 2: NLR in Study Subjects

From Table 1 it can be observed that mean age of the subjects was 52.49±8.18 years and mean BMI was 24.73±2.93 kg/m². Mean time since onset of chest pain was 4.71±1.36 hours. Mean NLR was 3.82±0.78 (Table 1).

Table 1: Descriptive Statistics of Risk Factors

Risk Factors	Minimum	Maximum	Mean	SD
Age	35.0	79.0	52.49	8.18
BMI	19.4	31.2	24.74	2.93
Time since onset of chest pain (hours)	1.0	8.0	4.71	1.36
ANC (10 ⁹ /L)	6.0	14.0	10.54	1.80
ALC	2.0	7.0	2.86	0.69
NLR	2.0	5.0	3.82	0.78

It is evident from Table 2 that successful thrombolysis was seen in 55 (76.39%) males and 44 (75.86%) females in their respective groups with p-value = 0.94. Data was stratified for age and successful thrombolysis was seen in 76 (73.79%) cases with age 25-59 years as compared to 23 (85.19%) with age 60-100 years with p-value=0.02 (Table 2). There were 53 (40.77%) smokers and success of thrombolysis was observed in 38 (71.70%). Successful thrombolysis was observed in 29 (67.44%) cases with high NLR and 70 (80.46%) cases with low NLR having p-value = 0.10. There was no significant difference in terms of data stratified for BMI, smoking, DM, HTN and the success of thrombolysis (Table 2).

Table 2: Percentage Distribution of Success of Thrombolysis across Risk Factors

Factors	Success of Thrombolysis		χ ² (p-value)
	Yes	No	
Gender			
Male	55 (76.39%)	17 (23.61%)	0.005 (0.94)
Female	44 (75.86%)	14 (24.14%)	
Age			
25-59	76 (73.79%)	27 (26.21%)	1.53 (0.22)
60-100	23 (85.19%)	4 (14.81%)	
BMI			
Up to 25	57 (75.00%)	19 (25.00%)	0.013 (0.71)
>25	42 (77.78%)	12 (22.22%)	
Smoking			
Yes	38 (71.70%)	15 (28.30%)	0.98 (0.32)
No	61 (79.22%)	16 (20.78%)	
DM			
Yes	59 (76.62%)	18 (23.38%)	0.02 (0.88)
No	40 (75.47%)	13 (24.53%)	
HTN			
Yes	32 (71.11%)	13 (28.89%)	0.96 (0.33)
No	67 (78.82%)	18 (21.18%)	
NLR			
High	29 (67.44%)	14 (32.56%)	2.69 (0.10)
Low	70 (80.46%)	17 (19.54%)	

DISCUSSION

Ischemic heart disease has been leading cause of deaths worldwide for last 15 years with more than 9M deaths in 2016^[9]. In Pakistan, leading cause of mortality is IHD as well, claiming 29 percent of total 1.4M deaths in 2016.^[10]

Although, the spectrum of IHD ranges from stable angina to ST segment elevation Myocardial infarction, underlying mechanism is mostly atherosclerosis, causing occlusion of the coronary arteries leading to supply & demand mismatch. When the atherosclerotic plaque is disrupted, platelet aggregation occurs at the site of injury & a thrombus is formed which can completely occlude the vessel & deprive myocardium of its blood supply,^[11] this is evident on an electrocardiogram (ECG) as an ST segment elevation myocardial infarction. The myocardium can be saved from necrosis, if timely revascularization is done; either with an invasive procedure like primary percutaneous intervention (PCI) or pharmacologically with thrombolytic agents like tissue plasminogen activator (tPA) or streptokinase (SK). Among patients with STEMI, patient's risk characteristics have an effect on early therapeutic decision^[12,13,14].

In this study, successful thrombolysis was observed in 99 (76.15%) out of the 130 cases presented with STEMI. These results were comparable with the findings of the previous studies where the success rate ranges from 50 to 80% of the cases^[15] and there are number of factors that are associated with its failure.

According to study done by Saleem et al, out of those 59 patients who received thrombolytic therapy before 12 hrs, 43 (72.8 percent) completely resolved. While those, who received thrombolytic therapy after 12 hrs, none of them completely resolved as per ECG result. These results were almost similar to the present study.^[16] This was also supported by study made in Shaikh Zayed Post-graduate Medical Institute Lahore Pakistan, where this efficacy was seen in 73% of the cases and they further described that mortality of patient decrease through giving thrombolytic within 12 hrs.^[17]

In another study made by Khaire U et al, they compared early vs late thrombolysis and it was observed that successful thrombolysis which was labelled on the basis of > 50% reduction in ST elevation, where there is beginning of therapy before 6 hrs and was noted in 54% of cases. Whereas only 41 (20.5 Percent) of cases shows improved ST segment > 50% after 6 hrs. of beginning of therapy and overall success rate was noted in 70.5% of cases.^[18]

The association between low lymphocyte count and major cardiovascular outcomes has also been shown in several studies.^[19,20] There is role of neutrophils and lymphocytes in

modulating the inflammation to myo cardiac injury^{21,22}In the present study Successful thrombolysis was observed in 29 (67.44%) cases with high NLR and 70 (80.46%) cases with low NLR with $p = 0.10$. The data in the past has shown that higher NLR at time of admission is related to increased morbidity & mortality in patients of acute coronary syndrome (ACS),^[23] even in the presence of a normal total leukocyte count (TLC). NLR also tends to be more in STEMI as compared to Non ST elevation ACS (NST-ACS), correlating with the severity of underlying occlusion.

While the significance of NLR in acute coronary syndrome (ACS) is an ongoing area of research, previous studies have seen the relationship of NLR with cardiac biomarkers,^[24] spontaneous resolution after MI, complications after thrombolysis,^[25] infarct size or coronary re-flow after PCI. Although, PCI is the gold standard for revascularization, however, the expertise is not freely available round the clock in Pakistan & only selected patients can undergo primary PCI. Majority of STEMI patients are managed with intravenous (IV) thrombolytic, mostly SK as it is readily available & is relatively, cost-effective. A significant proportion of patients still require rescue PCI because of the failure of SK to relieve chest pain & resolve ECG changes.

Gul et al further described, more complications had been observed (63.5% vs 25.5%, p -value<0.0001) in high Neutrophil Lymphocyte Ratio (NLR) cluster as compared to those who had low NLR. Incidence of death was found more for patients with high median NLR while median NLR was low for those who were discharged. NLR was found as the significant covariate of mortality (OR=1.131; p -value=0.029).^[26]

Several studies show NLR is a prognostic marker in patients with coronary artery disease^{27,28,29,30}. study done by Baysal et al determined the association of admission NLR & Red cell distribution width (RDW) with thrombolysis outcome using tPA&Tenecteplase on 102 patients. Their results showed that thrombolysis was successful in 70 (68.63%) and failed in 32 (31.37%) patients which was almost similar to the result of present study showing effective thrombolysis in 76.15% of total cases. The thrombolysis failure group had high NLR (4.2 ± 1.7) as compared to thrombolysis successful group (3.2 ± 2.3) with $p=0.028$ in Baysal's study. High RDW (>14.3 fl) was associated with high NLR (4 ± 2.5) & increased rate of thrombolysis failure (51.8%) as compared to low RDW which was associated with a lower NLR (2.8 ± 1.5) & a low thrombolysis failure rate (6.5%) with $p= 0.007$.^[31] Our study showed that 67.44% of the cases with high NLR had successful thrombolysis, as compared to 80.46% of the cases with low NLR.

Pashapour et al in Tabriz, Iran studied the relationship of NLR & PLR using Reteplase as the thrombolytic agent. Insignificant association was found between either NLR or level of response to thrombolytic therapy (OR 1.209 at 95% CI, $p = 0.055$). Moreover, insignificant association was observed between NLR and ejection fraction. Increased NLR and PLR was observed to linked with an increase in the rate of cardiac complications in STEMI patients (OR 1.198 at 95% CI, $p = 0.016$).^[31]

There were a few limitations to this study as it didn't compare the successful outcome of STEMI with other treatment modalities like other thrombolytic agents like tPA or with primary angioplasty. However risk stratification prior to intervention has great clinical importance to identify patients at high risk and optimize therapeutic management by intervention with PCI^[32,33].

However, there were many strengthening points as well, as this study showed good success rate even with a relatively cheaper thrombolytic agent; though complication rates were not studied. It also assessed another cheaper and readily available routine blood marker i.e. NLR to look for its prognostic value in relation to success of thrombolysis. Though there was a higher success rate in patients with a low admission NLR, however it was not found to be statistically significant.

CONCLUSION

Successful thrombolysis was seen in almost 3/4th cases in acute STEMI treated with Streptokinase and there was no significant

difference in terms of any of the confounders of the study. Moreover, although a cheaper and readily available prognostic tool, no statistically significant difference was found in terms of the admission NLR and the success of thrombolysis. However as various studies showed complications of STEMI and high NLR so patients with high NLR should be preferred for further work up and early time for intervention even after successful thrombolysis.

REFERENCES

1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2014 Dec 23; 64(24):e139-228.
2. McGill Jr HC, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP, Youth Research Group FT. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. *Arteriosclerosis, thrombosis, and vascular biology*. 2000 Aug; 20(8):1998-2004.
3. Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, Finn AV, Gold HK. Pathologic assessment of the vulnerable human coronary plaque. *Heart*. 2004 Dec 1; 90(12):1385-91.
4. Reddy KS. Cardiovascular disease in non-Western countries. *New England Journal of Medicine*. 2004 Jun 10; 350(24):2438-40.
5. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. *American heart journal*. 2004 Jul 1; 148(1):7-15.
6. Trialists FT. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. *The lancet*. 1994 Feb 5; 343(8893):311-22.
7. White HD. Thrombolytic therapy in the elderly. *Lancet*. 2000 Dec 1; 356(9247):2028-30.
8. Sawant AC, Adhikari P, Narra SR, Srivatsa SS, Mills PK, Srivatsa SS. Neutrophil to lymphocyte ratio predicts short-and long-term mortality following revascularization therapy for ST elevation myocardial infarction. *Cardiology journal*. 2014; 21(5):500-8.
9. World Health Organization. Fact sheet: The top 10 causes of death. 24.05.2018 [cited 15.11.2018]; [about 2am]. Available from: 113 <http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
10. World Health Organization. Non Communicable Diseases Country Profiles, 2018 [cited 15.11.2018]; [about 2 am]. Available at http://www.who.int/nmh/countries/pak_en.pdf
11. Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison's principles of internal medicine, 19e. New York, NY, USA: Mcgraw-hill; 2015.
12. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. *Lancet*. 1994;343:311-22. [PubMed] [Google Scholar]
13. Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice: the National Registry of Myocardial Infarction (NRMI-2) Participants. *Am Heart J*. 1998;135:786-96. [PubMed] [Google Scholar]
14. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK Investigators: should we emergently revascularize occluded coronaries for cardiogenic shock. *N Engl J Med*. 1999;341:625-34. [PubMed] [Google Scholar]
15. Baysal E, Çetin M, Yaylak B, Altıntaş B, Altındag R, Adyaman S, Altas Y, Kaya I, Sevik U. Roles of the red cell distribution width and neutrophil/lymphocyte ratio in predicting thrombolysis failure in patients with an ST-segment elevation myocardial infarction. *Blood Coagulation & Fibrinolysis*. 2015 Apr 1; 26(3):274-8.
16. Saleem S, Khan A, Shafiq I. Post thrombolytic resolution of ST elevation in STEMI patients. *Pakistan journal of medical sciences*. 2016 Jan; 32(1):201.
17. CH MR, Butt AK. Thrombolysis with intravenous streptokinase dose not alter 72-hours mortality in acute myocardial infarction. *Pakistan Heart Journal*. 2000; 32(1-4).

18. Khaire U, Shinde S. Comparison of Thrombolysis Outcome in Early and Late Thrombolysis in Acute STEMI Patients. *Int J Sci Res.* 2018; 7:426.
19. Zouridakis EG, GarciaMoll X, Kaski JC. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. *Am J Cardiol.* 2000;86:449451. [PubMed] [Google Scholar]
20. 18. Ommen SR, Hammill SC, Gibbons RJ. The relative lymphocyte count predicts death in patients receiving implantable cardioverter defibrillators. *Pacing Clin Electrophysiol.* 2002;25:1424–8. [PubMed]
21. Duffy BK, Gurm HS, Rajagopal V, et al. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. *Am J Cardiol.* 2006;97:993–6. [PubMed] [Google Scholar]
22. 40. Anderson JL, Ronnow BS, Horne BD, et al. Usefulness of a complete blood count derived risk score to predict incident mortality in patients with suspected cardiovascular disease. *Am J Cardiol.* 2007;99:169–74. [PubMed] [Google Scholar]
23. Bajari R, Tak S. Predictive prognostic value of neutrophil–lymphocytes ratio in acute coronary syndrome. *Indian heart journal.* 2017 Apr 1; 69:S46-50.
24. Korkmaz A, Yildiz A, Gunes H, Duyuler S, Tuncez A. Utility of neutrophil–lymphocyte ratio in predicting troponin elevation in the emergency department setting. *Clinical and applied thrombosis/hemostasis.* 2015 Oct; 21(7):667-71.
25. Gul U, Kayani AM, Munir R, Hussain S. Neutrophil lymphocyte ratio: A prognostic marker in acute ST elevation myocardial infarction. *J Coll Physicians Surg Pak.* 2017 Jan 1; 27(1):4-7.
26. Pashapour P, Ghaffarii S, Separham A. The relationship of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in peripheral
27. Kaya H, Ertas F, Islamoglu Y, et al. MS Association between neutrophil to lymphocyte ratio and severity of coronary artery disease. *Clin Appl Thromb Hemost.* 2014;20:50–4. [PubMed] [Google Scholar]
28. 14. Acet H, Ertaş F, Akıl MA, et al. New inflammatory predictors for non-valvular atrial fibrillation: echocardiographic epicardial fat thickness and neutrophil to lymphocyte ratio. *Int J Cardiovasc Imaging.* 2014;30:81–9. [PubMed] [Google Scholar]
29. Sen N, Afsar B, Ozcan F, et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. *Atherosclerosis.* 2013;228:203–10. [PubMed] [Google Scholar]
30. 42. Isik T, Ayhan E, Uyarel H, et al. Association of neutrophil to lymphocyte ratio with presence of isolated coronary artery ectasia. *Turk Kardiyol Dern Ars.* 2013;41:123– [PubMed] [Google Scholar]
31. blood with ST-segment resolution and the clinical outcomes of STEMI patients receiving thrombolytic therapy. *Romanian Journal of Internal Medicine.* 2019 Mar 1; 57(1):47-54.
32. Addala S, Grines CL, Dixon SR, et al. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score) *Am J Cardiol.* 2004;93:629–32. [PubMed] [Google Scholar]
33. 10. Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. *J Am Coll Cardiol.* 2005;45:1397–405. [PubMed] [Google Scholar]